REVIEW OF GOUTY ARTHRITIS: A NEW PERCEPTION FOR THE TREATMENT OF OLD DISEASES
AbstractGouty arthritis, an inflammatory joint disease, occurs due to the accumulation of Monosodium Urate (MSU) crystals in the joints, mainly at the metatarsophalangeal joints of the big toe. At present, the incidence and prevalence of gout are increasing globally. The various risk factors are responsible for the development of gouty arthritis, including nonmodifiable, modifiable, and genetic factors. Under physiological conditions, the purine undergoes a catabolic pathway to produce the uric acid end product excreted from the body using various uric acid transporters. The overproduction or under-excretion of uric acid leads to the pathophysiology of hyperuricemia and promotes the MSU crystals formation and deposition in joints to trigger inflammation by releasing inflammatory mediators in gouty arthritis. If chronic gout has been left untreated, the pain worsens and eventually causes cartilage degradation, bone erosion, and urolithiasis. The research studies of the antigout activity of the various secondary metabolites are manifested in this review. The inflammatory pathways involved in gouty arthritis development are being discussed to find a new therapeutic target to treat gouty arthritis better.
Article Information
17
4404-4418
1120 KB
263
English
IJPSR
P. Manimekalai *, C. Sabarinath, M. Sowndharya, N. T. Yazhini, M. Nivetha, J. Thendral and S. Bhuvaneshwari
Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Tiruchengode-, Namakkal, Tamil Nadu, India.
Pharmacologyproject06@gmail.com
25 January 2023
31 March 2023
25 April 2023
10.13040/IJPSR.0975-8232.14(9).4404-18
01 September 2023
Download